AD
ADGM.US Adagio Medical Holdings, Inc Common Stock
- Market cap
- USD 49.9M
- P/E
- -
- P/B
- 2.89x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ADGM.US undervalued?
Graham numberThe Graham number of Adagio Medical Holdings, Inc Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adagio Medical Holdings, Inc Common Stock fundamental analysis
No fundamental analysis for Adagio Medical Holdings, Inc Common Stock yet.
Adagio Medical Holdings, Inc Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adagio Medical Holdings, Inc Common Stock
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. …
Full company profileAdagio Medical Holdings, Inc Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adagio Medical Holdings, Inc Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 270K | 189K | 300K | 269K | 0.00 | 0.00 |
| Gross Profit | - | -888K | -686K | -1.01M | -1.67M | -684K | -822K |
| Operating Income | -13.5K | -20.6M | -23.9M | -27.9M | -62.5M | -21.9M | -20.3M |
| EBITDA | -13.5K | -19.6M | -23.0M | -36.0M | -53.5M | -21.2M | -23.4M |
| Net Income | -13.5K | -19.9M | -23.7M | -38.1M | -53.8M | -25.1M | -27.4M |
| EPS | 0.00 | -1.04 | -37 | -85 | -106 | -45 | -37 |
| Balance Sheet | |||||||
| Total Assets | 42.5K | 21.4M | 8.70M | 6.83M | 48.4M | 43.3M | 33.9M |
| Total Liabilities | 56.0K | 94.1M | 105M | 139M | 28.5M | 30.9M | 34.3M |
| Shareholders' Equity | -13.5K | -72.6M | -95.9M | -132M | 19.9M | 12.4M | -415K |
| Cash & Short-term Investments | - | 18.9M | 5.55M | 1.38M | 20.6M | 17.1M | 7.74M |
| Total Debt | 11.2K | - | 9.80M | 38.4M | 16.3M | 21.8M | 26.0M |
| Cash Flow | |||||||
| Operating Cash Flow | - | -19.3M | -22.4M | -726K | -29.5M | -19.0M | -18.8M |
| Capital Expenditure | - | 1.27M | 492K | 2.00 | 1.65M | 374K | 16.0K |
| Free Cash Flow | - | -20.6M | -22.9M | -726K | -31.1M | -19.4M | -18.8M |
| Ratios | |||||||
| ROE | - | - | - | - | -270.0% | -202.3% | - |
| ROA | -31.9% | -93.0% | -272.2% | -558.9% | -111.0% | -58.0% | -80.9% |
| Net Profit Margin | - | -7,384.4% | -12,525.4% | -12,715.3% | -19,986.2% | - | - |
| Debt to Equity | - | - | - | - | 0.82x | 1.75x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adagio Medical Holdings, Inc Common Stock dividends
Adagio Medical Holdings, Inc Common Stock has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Nov 9, 2026.
Who owns Adagio Medical Holdings, Inc Common Stock
- Insiders 0.95%
- Institutions 53.04%
- Public & others 46.01%
- Shares outstanding 27.4M
- Free float 281K
Top funds holding ADGM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 576K | 0.07% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 50.5K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 18.4K | 0.00% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 17.4K | 0.00% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 10.4K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding ADGM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.88M | 36.33% | +0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.26M | 4.63% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.21M | 4.43% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 1.16M | 4.27% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 699K | 2.57% | -45.75% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 224K | 0.83% | -10.96% | Jun 2026 |
| Shaolin Capital Management LLC | 171K | 0.63% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 109K | 0.40% | +175.08% | Jun 2026 |
| Affinity Asset Advisors, LLC | 80.0K | 0.29% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 79.1K | 0.29% | -36.83% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 53.8K | 0.20% | 0.00% | Jun 2026 |
| Northern Trust Corp | 30.9K | 0.11% | +42.95% | Jun 2026 |
| The Toronto-Dominion Bank | 25.0K | 0.09% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 18.4K | 0.07% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 18.2K | 0.07% | -22.26% | Jun 2026 |
| Citadel Advisors Llc | 16.2K | 0.06% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 13.7K | 0.05% | 0.00% | Jun 2026 |
| Citigroup Inc | 13.3K | 0.05% | +1,325,400.00% | Jun 2026 |
| Bank of America Corp | 11.5K | 0.04% | -10.31% | Jun 2026 |
| Tower Research Capital LLC | 6.45K | 0.02% | +193.10% | Jun 2026 |
Adagio Medical Holdings, Inc Common Stock company profile
- Company name
- Adagio Medical Holdings, Inc Common Stock
- Ticker
- ADGM.US
- Exchange
- USA Stocks
- Listed since
- Aug 1, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 41
- Fiscal year end
- December
- Address
- 26051 Merit Circle, Laguna Hills, CA, United States, 92653
- Phone
- 949 348 1188
- Website
- adagiomedical.com
About Adagio Medical Holdings, Inc Common Stock
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc Common Stock management
8- Mr. Todd UsenCEO & Director · born 1967
- Ms. Deborah KasterCFO & Chief Business Officer · born 1971
- Mr. Antwan Gipson M.B.A.Senior Vice President of Manufacturing & Operations
- Dr. Alex Babkin Ph.D.Chief Technical Officer
- Mr. Nabil JubranChief Compliance Officer
- Mr. Ilya GrigorovVice President of Global Marketing & Product Management
- Ms. Marie-Claude JacquesSenior Vice President of Global Sales · born 1985
- Ms. Maryline CullenVP & Corporate Controller